Published in Trends Pharmacol Sci on November 01, 2004
Mast cells and inflammation. Biochim Biophys Acta (2010) 1.91
Key role of CRF in the skin stress response system. Endocr Rev (2013) 1.77
Neuroimmunology of stress: skin takes center stage. J Invest Dermatol (2006) 1.72
Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy (2012) 1.66
Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol (2006) 1.60
Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci (2007) 1.50
BuShenYiQi granule inhibits atopic dermatitis via improving central and skin Hypothalamic-Pituitary-Adrenal axis function. PLoS One (2015) 1.39
CRH functions as a growth factor/cytokine in the skin. J Cell Physiol (2006) 1.38
Skin as an endocrine organ: implications for its function. Drug Discov Today Dis Mech (2008) 1.19
Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications. J Physiol Pharmacol (2009) 1.13
Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci U S A (2006) 1.10
Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. J Invest Dermatol (2011) 1.03
On the role of the corticotropin-releasing hormone signalling system in the aetiology of inflammatory skin disorders. Br J Dermatol (2009) 1.02
Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors. Brain Behav Immun (2009) 1.02
Role of inflammation in bladder function and interstitial cystitis. Ther Adv Urol (2011) 1.02
CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-α. PLoS One (2012) 1.01
Brain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. Front Neurosci (2015) 0.99
Emerging role of alternative splicing of CRF1 receptor in CRF signaling. Acta Biochim Pol (2010) 0.97
CRH inhibits NF-kappa B signaling in human melanocytes. Peptides (2006) 0.96
Mast cell: an emerging partner in immune interaction. Front Immunol (2012) 0.95
Critical role for mast cells in interleukin-1β-driven skin inflammation associated with an activating mutation in the nlrp3 protein. Immunity (2012) 0.95
Perinatal stress, brain inflammation and risk of autism-review and proposal. BMC Pediatr (2012) 0.94
CRH mediates inflammation induced by lipopolysaccharide in human adult epidermal keratinocytes. J Invest Dermatol (2006) 0.94
Footshock-induced urinary bladder hypersensitivity: role of spinal corticotropin-releasing factor receptors. J Pain (2008) 0.94
Evidence for CRHR1 in multiple sclerosis using supervised machine learning and meta-analysis in 12,566 individuals. Hum Mol Genet (2010) 0.93
Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor. Bioorg Med Chem (2015) 0.91
Chronic restraint stress inhibits hair growth via substance P mediated by reactive oxygen species in mice. PLoS One (2013) 0.87
Neurotensin and CRH interactions augment human mast cell activation. PLoS One (2012) 0.82
Proopiomelanocortin signaling system is operating in mast cells. J Invest Dermatol (2006) 0.82
Neuroendocrinology of the skin: An overview and selective analysis. Dermatoendocrinol (2011) 0.81
Possible involvement of TLRs and hemichannels in stress-induced CNS dysfunction via mastocytes, and glia activation. Mediators Inflamm (2013) 0.81
Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome. J Gastroenterol (2015) 0.81
Role of parasympathetic nerves and muscarinic receptors in allergy and asthma. Chem Immunol Allergy (2012) 0.81
Mast Cell-Mediated Mechanisms of Nociception. Int J Mol Sci (2015) 0.80
Isoflavones inhibit poly(I:C)-induced serum, brain, and skin inflammatory mediators - relevance to chronic fatigue syndrome. J Neuroinflammation (2014) 0.80
Stress triggers coronary mast cells leading to cardiac events. Ann Allergy Asthma Immunol (2013) 0.80
Serum neurotensin (NT) is increased in psoriasis and NT induces vascular endothelial growth factor release from human mast cells. Br J Dermatol (2012) 0.80
Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors. Br J Pharmacol (2009) 0.79
Mast Cells Regulate Wound Healing in Diabetes. Diabetes (2016) 0.79
Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: possible relevance to chronic fatigue syndrome. J Clin Psychopharmacol (2011) 0.78
Elevated serum neurotensin and CRH levels in children with autistic spectrum disorders and tail-chasing Bull Terriers with a phenotype similar to autism. Transl Psychiatry (2014) 0.78
Sphingosine-1-phosphate can promote mast cell hyper-reactivity through regulation of contactin-4 expression. J Leukoc Biol (2013) 0.78
Dermal microdialysis of inflammatory markers induced by aliphatic hydrocarbons in rats. Toxicol Lett (2008) 0.78
Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome. World J Gastroenterol (2011) 0.77
Mast cells in irritable bowel syndrome and ulcerative colitis: function not numbers is what makes all the difference. Dig Dis Sci (2014) 0.77
Cutaneous induction of corticotropin releasing hormone by Propionibacterium acnes extracts. Dermatoendocrinol (2009) 0.76
Stress-induced mast cell activation in glabrous and hairy skin. Mediators Inflamm (2014) 0.76
Genitourinary mast cells and survival. Transl Androl Urol (2015) 0.75
Fatigue and interleukin-6 - a multi-faceted relationship. Reumatologia (2015) 0.75
Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration. Front Cell Neurosci (2017) 0.75
Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells. Immunol Res (2017) 0.75
Vitiligo: what's new in the psycho-neuro-endocrine-immune connection and related treatments. Wien Med Wochenschr (2014) 0.75
Thalamic mast cell activity is associated with sign-tracking behavior in rats. Brain Behav Immun (2017) 0.75
Evidence for the modulation of nociception in mice by central mast cells. Eur J Pain (2017) 0.75
ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell (2009) 9.24
mTOR regulation of autophagy. FEBS Lett (2010) 6.59
Effect size estimation: a necessary component of statistical analysis. Arch Surg (2009) 3.41
Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat Immunol (2008) 2.32
Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev (2007) 1.94
Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol (2004) 1.79
Essential role for IkappaB kinase beta in remodeling Carma1-Bcl10-Malt1 complexes upon T cell activation. Mol Cell (2006) 1.78
IL-10, an inflammatory/inhibitory cytokine, but not always. Immunol Lett (2003) 1.76
The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology (2007) 1.67
IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A (2010) 1.56
High levels of intrauterine corticotropin-releasing hormone, urocortin, tryptase, and interleukin-8 in spontaneous abortions. Endocrinology (2003) 1.52
Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics. J Clin Psychopharmacol (2005) 1.49
Corticotropin-releasing hormone-receptor 2 is required for acute stress-induced bladder vascular permeability and release of vascular endothelial growth factor. BJU Int (2010) 1.46
Impact of stress and mast cells on brain metastases. J Neuroimmunol (2008) 1.46
Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol (2005) 1.45
Acute stress-induced seizures and loss of consciousness in a ten-year-old boy with cutaneous mastocytosis. J Clin Psychopharmacol (2002) 1.45
Chronic fatigue syndrome, mast cells, and tricyclic antidepressants. J Clin Psychopharmacol (2005) 1.44
Procedure volume as a predictor of surgical outcomes. JAMA (2010) 1.35
Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci (2006) 1.31
Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol (2005) 1.31
Mouse Eri1 interacts with the ribosome and catalyzes 5.8S rRNA processing. Nat Struct Mol Biol (2008) 1.26
Proteomics analysis of cells in whole saliva from oral cancer patients via value-added three-dimensional peptide fractionation and tandem mass spectrometry. Mol Cell Proteomics (2007) 1.19
Brain cytokines and neuropsychiatric disorders. J Clin Psychopharmacol (2004) 1.14
IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol (2003) 1.11
Two highly related regulatory subunits of PP2A exert opposite effects on TGF-beta/Activin/Nodal signalling. Development (2008) 1.11
Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci U S A (2006) 1.10
Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. J Clin Psychopharmacol (2007) 1.09
Spectrum of mast cell activation disorders. Expert Rev Clin Immunol (2014) 1.08
Advances in therapy with antileukotriene drugs. Ann Clin Lab Sci (2004) 1.07
Tandem 18O stable isotope labeling for quantification of N-glycoproteome. J Proteome Res (2010) 1.07
[Polychaete community in mangrove and salt marsh in Zhangjiang River Estuary, Fujian Province of East China]. Ying Yong Sheng Tai Xue Bao (2012) 1.07
Pharmacology and immunological actions of a herbal medicine ASHMI on allergic asthma. Phytother Res (2010) 1.07
A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol (2010) 1.04
Fluorescence interferometry: principles and applications in biology. Ann N Y Acad Sci (2008) 1.00
Listeria monocytogenes infection in macrophages induces vacuolar-dependent host miRNA response. PLoS One (2011) 0.97
Identifying the sources and fate of anthropogenically impacted dissolved organic matter (DOM) in urbanized rivers. Water Res (2013) 0.96
A close examination of double filtering with fold change and T test in microarray analysis. BMC Bioinformatics (2009) 0.96
Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroimmunol (2004) 0.96
Autism: an emerging 'neuroimmune disorder' in search of therapy. Expert Opin Pharmacother (2009) 0.95
Tread carefully with stepwise regression. Arch Surg (2010) 0.94
GO-Bayes: Gene Ontology-based overrepresentation analysis using a Bayesian approach. Bioinformatics (2010) 0.93
Calculating sample size in trials using historical controls. Clin Trials (2010) 0.93
Inducible nitric oxide synthase and heme oxygenase-1 in rat heart: direct effect of chronic exposure to hypoxia. Ann Clin Lab Sci (2003) 0.93
Novel therapeutic targets for autism. Trends Pharmacol Sci (2008) 0.92
Skin corticotropin-releasing hormone receptor expression in psoriasis. J Invest Dermatol (2007) 0.92
Human mast cells stimulate activated T cells: implications for multiple sclerosis. Ann N Y Acad Sci (2008) 0.92
Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy. Cancer Immunol Immunother (2002) 0.91
De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients. Hepatol Int (2011) 0.90
Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin. Br J Pharmacol (2006) 0.90
Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease. Ann Clin Lab Sci (2005) 0.90
Nitric oxide enhances the sensitivity of alpaca melanocytes to respond to alpha-melanocyte-stimulating hormone by up-regulating melanocortin-1 receptor. Biochem Biophys Res Commun (2010) 0.90
Phloem transdifferentiation from immature xylem cells during bark regeneration after girdling in Eucommia ulmoides Oliv. J Exp Bot (2008) 0.89
Ultrasensitive DNAzyme beacon for lanthanides and metal speciation. Anal Chem (2014) 0.89
Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants. Atherosclerosis (2010) 0.88
Enhanced expression of glia maturation factor correlates with glial activation in the brain of triple transgenic Alzheimer's disease mice. Neurochem Res (2012) 0.88
Effect of fur removal on the thermal conductance and energy budget in lactating Swiss mice. J Exp Biol (2009) 0.88
Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model. J Pharmacol Exp Ther (2008) 0.88
IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells. Eur J Dermatol (2010) 0.88
cAMP-dependent protein kinase activated Fyn in spinal dorsal horn to regulate NMDA receptor function during inflammatory pain. J Neurochem (2010) 0.87
[Secondary productivity of macrobenthos in mangrove and salt marsh in Gaoqiao of Zhanjiang, Guangdong Province of South China]. Ying Yong Sheng Tai Xue Bao (2012) 0.87
Interleukin-16 network in inflammation and allergy. Allergy Asthma Proc (2002) 0.87
Increased numbers of activated mast cells in endometriosis lesions positive for corticotropin-releasing hormone and urocortin. Am J Reprod Immunol (2004) 0.87
Modulation of MCP-1 and iNOS by 50-Hz sinusoidal electromagnetic field. Nitric Oxide (2006) 0.86
Mitochondrial uncoupling protein 2 inhibits mast cell activation and reduces histamine content. J Immunol (2009) 0.86
Th2 cytokine-induced upregulation of 11beta-hydroxysteroid dehydrogenase-1 facilitates glucocorticoid suppression of proasthmatic airway smooth muscle function. Am J Physiol Lung Cell Mol Physiol (2009) 0.86
Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation. Allergy Asthma Proc (2003) 0.86
Molecular classification of nodal metastasis in primary larynx squamous cell carcinoma. Transl Res (2007) 0.86
PopW of Ralstonia solanacearum, a new two-domain harpin targeting the plant cell wall. Mol Plant Pathol (2010) 0.85
Polygenic association with total homocysteine in the post-folic acid fortification era: the CARDIA study. Mol Genet Metab (2009) 0.85
Discovery and confirmation of O-GlcNAcylated proteins in rat liver mitochondria by combination of mass spectrometry and immunological methods. PLoS One (2013) 0.85
The energy budget, thermogenic capacity and behavior in Swiss mice exposed to a consecutive decrease in temperatures. J Exp Biol (2010) 0.85
Effects of resveratrol on lymphocyte proliferation and cytokine release. Ann Clin Lab Sci (2003) 0.85
NR2B phosphorylation at tyrosine 1472 in spinal dorsal horn contributed to N-methyl-D-aspartate-induced pain hypersensitivity in mice. J Neurosci Res (2011) 0.84
Urocortin induces interleukin-6 release from rat cardiomyocytes through p38 MAP kinase, ERK and NF-kappaB activation. J Mol Endocrinol (2009) 0.84
The Drosophila homolog of human tumor suppressor TSC-22 promotes cellular growth, proliferation, and survival. Proc Natl Acad Sci U S A (2008) 0.84
De novo characterization of Lentinula edodes C(91-3) transcriptome by deep Solexa sequencing. Biochem Biophys Res Commun (2012) 0.84
A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy. J Clin Psychopharmacol (2012) 0.84
Interleukin-17 and the interleukin-17 family member network. Allergy Asthma Proc (2004) 0.83
Synthesis, complexation, and fluorescence behavior of 3,4-dimethylthieno[2,3-b]thiophene carrying two monoaza-15-crown-5 ether groups. Spectrochim Acta A Mol Biomol Spectrosc (2011) 0.83
Systemic inflammation with multiorgan dysfunction is the cause of death in murine ligation-induced acute pancreatitis. J Gastrointest Surg (2011) 0.83
Milk energy output during peak lactation in shaved Swiss mice. Physiol Behav (2010) 0.83
Interferon beta-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis. J Neuroimmunol (2002) 0.83
Alpha-1 antitrypsin variants in plasma from HIV-infected patients revealed by proteomic and glycoproteomic analysis. Electrophoresis (2010) 0.83
Plasticity in energy budget and behavior in Swiss mice and striped hamsters under stochastic food deprivation and refeeding. Comp Biochem Physiol A Mol Integr Physiol (2009) 0.83
Interleukin-6 and mast cells. Allergy Asthma Proc (2002) 0.82
Protection of MPTP-induced neuroinflammation and neurodegeneration by Pycnogenol. Neurochem Int (2013) 0.82
IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors. Exp Gerontol (2004) 0.82
Mast cells, T cells, and inhibition by luteolin: implications for the pathogenesis and treatment of multiple sclerosis. Adv Exp Med Biol (2007) 0.82
Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists. Int Arch Allergy Immunol (2003) 0.82
Brain inflammation, neuropsychiatric disorders, and immunoendocrine effects of luteolin. J Clin Psychopharmacol (2014) 0.82